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Common Variable Immunodeficiency (CVID) is a group of heterogeneous primary
immunodeficiencies sharing defective B lymphocytes maturation and dysregulated
immune response and resulting in impaired immunoglobulin production. Clinical
picture encompasses increased susceptibility to infections, hematologic malignancies,
inflammatory, and autoimmune diseases. Neurological manifestations are uncommon
and optic neuritis has been previously reported only in one casewith bilateral involvement.
We hereby report a case of a 26-year-old man affected by CVID undergoing regular
immunoglobulin supplementation, who presented with acute unilateral demyelinating
optic neuritis and lymphocytic pleocytosis in the cerebrospinal fluid. A variety of infectious,
inflammatory, and neoplastic conditions were excluded and a diagnosis of clinically
isolated optic neuritis was made. The patient was treated with a short course of
intravenous steroids with complete recovery. Overall, this case expands our current
knowledge about clinical spectrum of complications in CVID and highlights the need
for further research about this complex disease.
Keywords: common variable immunodeficiency, optic neuritis, optic neuropathy, clinically isolated syndrome,
autoimmunity, primary immunodeficiencies
BACKGROUND
Common Variable Immunodeficiency (CVID) is a group of primary immunodeficiencies
characterized by an impairment in antibody production related to B cell intrinsic or extrinsic
defects (1). CVID is defined by increased susceptibility to infection, autoimmune manifestations,
granulomatous disease, and unexplained polyclonal lymphoproliferation associated to markedly
reduced levels (2 SD below the mean) of serum immunoglobulin (Ig) G, as well as IgA and/or
IgM, failed antibody response to natural infections or vaccine immunization and reduction of
switched memory B cells, with the exclusion of secondary causes of hypogammaglobulinemia and
no evidence of profound T-cell deficiency or T-cell proliferation (1–3). Clinical manifestations
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are heterogeneous and include increased susceptibility
to infections, autoimmune manifestations, malignancies,
granulomatous disease, and unexplained polyclonal
lymphoproliferation, affecting multiple organ systems (2, 4–
7). Among autoimmune disorders, the most common are
thrombocytopenia, hemolytic anemia, and rheumatologic
disorders (4, 6–8). Neurologic complications are rare,
and include a variety of central nervous system (CNS)
infections, the most common being bacterial meningitis
and viral meningoencephalitis, autoimmune/inflammatory
encephalomyelitis or peripheral neuropathies (9). Only one case
of bilateral posterior optic neuritis is reported (10).
Acute optic neuritis (ON) is caused by inflammation of the
optic nerve and represents the most common optic neuropathy
affecting young adults (11). Typical ON presents with subacute,
monocular visual defects, which include a decrease in visual and
contrast acuity, focal campimetric deficits, diffuse blurring or
fogging of vision, and dyschromatopsia, generally associated with
pain on eye movements (11). Relative afferent pupillary defect is
also commonly observed (11). In the majority of cases, ON is a
manifestation of multiple sclerosis (MS). Other potential causes
include Acquaporin 4 (AQP4)-IgG-positive neuromyelitis optica
spectrum disorders (NMOSD) (12) and Myelin oligodendrocyte
glycoprotein (MOG)-IgG-associated encephalomyelitis (13), in
addition to systemic autoimmune disorders such as connective
tissue diseases, vasculitides, or sarcoidosis (11). A variety of
bacterial, viral, parasitic, and fungal infectious agents can also be
responsible for ON (14).
Here, we present a case of a young man with CVID and acute
onset of unilateral inflammatory optic neuritis.
CASE PRESENTATION
A 27-year-old man was admitted to our Emergency Department
for a 3-days-history of blurry vision in his left eye. His medical
history included CVID: during early childhood, he experienced
multiple respiratory tract infections and selective IgA deficiency
was diagnosed. At the age of 11, he developed splenomegaly
and multiple abdominal and thoracic lymphadenopathies.
At the age of 14, histological analysis of an inguinal lymph
node was performed, showing reactive lymphadenopathy
and no evidence of lymphoproliferative disease. Serum IgG
were 593 mg/dL, IgM 50 mg/dL, IgA 6 mg/dl. Few months
later he developed severe immune thrombocytopenic purpura
(ITP), successfully treated with a course of intravenous
immunoglobulins. Autoimmune/lymphoproliferative syndrome
(ALPS) was excluded based on negative molecular analysis for
TNFRSF6. No further investigations for lymphoproliferation
and hypogammaglobulinemia were done at that time. At the
age of 21, he experienced recurrent prostatic infections and
Herpes Zoster reactivation on the trunk. After a long delay,
at the age of 23, diagnosis of CVID was made according to
the criteria developed by the European Society for Immune
Deficiencies (ESID) and the International Consensus on
CVID (2, 3). He presented recurrent sinusitis, splenomegaly,
laterocervical, axillary, and inguinal lymphoadenopathy. Total
IgG, IgM, and IgA count at diagnosis was 150 mg/dL, 6 mg/dl,
and 0, respectively. Lymphocytes immunophenotyping and
maturative analysis revealed normal levels of circulating B cells
(341/µL), failure of B lymphocytes maturation with reduced
levels of switched memory B cells (0.6%), and increase in
CD21 low subpopulation (22%). T and NK cell subsets were
in normal range. Serum β2-microglulin was 3.54 mg/dL (n.r.
0.8–2.2). Molecular analyses for HIV, EBV, CMV, Toxoplasma
were negative. Lymphoma was ruled out by bone marrow
trephine biopsy and total body Computed Tomography (CT)-
scans showed no change in previously described thoracic
and abdominal lymphadenopathies and splenomegaly.
Other causes of secondary hypogammaglobulinemia were
excluded. Therefore, replacement therapy with intravenous
immunoglobulins (0.4 g/kg every 3 weeks) was started and the
patient was addressed to CVID protocol for follow up since then.
At presentation, the patient reported decreased visual acuity
and partial loss of color vision on his left eye. Neurologic
examination showed reduced visual acuity, relative paracentral
scotoma and red desaturation in the left eye, moderate pain
on pressure of the ipsilateral ocular bulb, but no pain on
ocular movements. Pupillary light reflex was reduced on the
same side, and relative afferent pupillary defect or Marcus-
Gunn pupil was present. The right eye was unaffected and
the remaining neurological examination was unremarkable.
Fundoscopic evaluation revealed a sharp-edged optic disk in
absence of stasis signs and retinal lesions. Optical coherent
tomography (OCT) showed normal retinal morphology and
thickness. Brain and spinal cord Magnetic Resonance Imaging
(MRI) demonstrated enlargement and hyperintensity of the left
optic nerve in its posterior portion, with intense enhancement
after the administration of gadolinium (Figure 1). Pattern shift
visual evoked potentials showed a marked delay of the P100
component with an attenuation of the P100 wave amplitude
in the left eye (Figure 2). Cerebral spinal fluid (CSF) analysis
revealed marked pleocytosis (200 cells/ul) with lymphocyte
prevalence, and mildly elevated protein level (56 mg/dl).
Oligoclonal bands were absent. PCR for HIV, HSV 1, HSV2,
HHV6, HHV8, EBV, VZV, Parvovirus, Adenovirus, Enterovirus,
BKV, Pneumococcus, Streptococcus group B, Cryptococcus,
and Toxoplasma did not detect any infection. CSF cultures
were negative. Serum anti-AQP4 and anti-MOG antibodies
were absent. Likewise, anti-nuclear antibodies, anti-extractable
nuclear antigens antibodies, anti-double strand DNA antibodies,
and anti-tireoperoxidase antibodies turned out negative.
Routine blood examination showed mild leukopenia
(3,250/ul) and low platelet count (72,000/uL). Serum IgG
and IgM levels were, respectively, 764 mg/dL and 8 mg/dL,
while serum IgA were undetectable. Circulating lymphocytes
were 1463/µL, (CD3+ 835/µL, CD4+ 559/µL, CD8+
Abbreviations: AQP4, Acquaporin 4; CNS, Central Nervous System; CSF,
Cerebral spinal fluid; CT, Computed Tomography; CVID, Common Variable
Immunodeficiency; Ig, Immunoglobulin; MOG, Myelin oligodendrocyte
glycoprotein; MRI, Magnetic Resonance Imaging; MS, Multiple Sclerosis;
NHL, Non-Hodgkin lymphoma; NMOSD, Neuromyelitis Optica Spectrum
Disorder; OCT, Optical Coherence Tomography; ON, Optic Neuritis; PET,
Positron Emission Tomography.
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FIGURE 1 | Enlargement and hyperintensity of the optic nerve in fat-suppression MRI techniques (Short-tau inversion recovery or STIR sequence on the left and
spectral presaturation with inversion recovery or SPIR sequence on the right). Fat-suppression sequences are useful to identify signal abnormalities of structures
surrounded by fatty tissues, such as the optic nerve.
240/µL, CD19+ 536/µL, CD16+56+ 84/µL). Lymphocytes
immunophenotyping and maturative analysis showed decreased
NK cells (84/uL), failure of maturation of B lymphocytes
with markedly reduced switched memory B cells (0.6%),
transitional B cells (0.1%) and plasmablasts (0.2%), and
further increased CD21 low subpopulation (36.7%). Infection
markers resulted within normal range. Serum β2-microglulin
was slightly increased compared to baseline (4.09 mg/dL;
n.r. 0.8–2.2).Serum PCR for HIV, HSV 1, HSV2, HHV6,
HHV8, EBV, VZV, Parvovirus, Adenovirus, Enterovirus, BKV,
Pneumococcus, Streptococcus group B, Cryptococcus, and
Toxoplasma were negative. Serum serologies for Treponema
pallidum, Borrelia burgdorferi, Bartonella henselae, and
Brucella were negative, as well as QuantiFERON gold test for
Mycobacterium tubercolosis and serum galactomannan assay for
Aspergillus detection.
Given the higher susceptibility of CVID patients to
lymphoproliferative diseases, cytological and radiological
examinations were carried out in order to exclude CNS
lymphoma. No malignant cells were detected in the CSF.
Total body Positron Emission Tomography (PET)/CT study
with 18-FDG did not show any focal increase in glucose
metabolism.
As soon as viral infections were excluded, our patient was
treated with an empiric course of IV methylprednisolone
(1 g/die for 5 days) and a tapering course of prednisone,
as early IV steroidal therapy was shown to accelerate
clinical resolution in patients with autoimmune ON. IV
ceftriaxone and oral Bactrim were added while waiting
for microbial cultures results. Given the history of Zoster
reactivation, prophylactic therapy with oral Acyclovir
was administered to the patient in concomitance with
steroidal therapy. The patient reported a rapid clinical
improvement following the administration of the first
methylprednisolone dose, with complete regression of
symptoms in 4 days, and remained asymptomatic at 6-month
follow-up.
DISCUSSION
Although long known, the pathophysiology of CVID has
not been completely elucidated yet. Despite few monogenic
defects have been identified in a subset of CVID patients,
the clinical heterogeneity of this condition suggests that
it is a polygenic disorder which encompasses multiple
molecular alterations resulting in a common final endpoint
of hypogammaglobulinemia and dysregulated immune response
(1, 15, 16). Primary B-cell dysfunction and defects in T-cells
and antigen-presenting cells can be observed (17). Moreover, B
lymphocytes typically fail to differentiate into switched memory
B cells and plasma cells, and a reduction in switched memory B
cells is invariably observed (15, 18). Notably, switched memory
B cells develop in the germinal center in a T-dependent fashion,
therefore their reduction could be ascribed both to T and B
cells dysfunctions (15, 17). Indeed, several abnormalities in
CD4+ and CD8+ T cells proliferation, activation, survival and
secretory functions have been found in these patients (15, 17, 18).
Moreover, suppressive functions of T-regulatory (Treg) cells
are altered (19). These alterations are associated with a chronic
immune activation and with high incidence of autoimmunity.
Indeed, although it may seem paradoxical, CVID is
characterized by an increased susceptibility to autoimmunity,
malignancies and inflammatory conditions (20). Autoimmune
cytopenias are diagnosed in almost 25% of CVID patients
and can be the presenting disorder (18, 21). Autoimmunity
is a manifestation of immune dysregulation, but its precise
mechanisms in CVID are still unclear. Expansion of CD21 low B
cells and reduction in Treg cells is frequently observed in CVID
and is associated with a clinical phenotype characterized by
autoimmunity and splenomegaly (22–24). Treg cells are a subset
of T cells able to produce cytokines, such as IL-10, IL-35, and
TGFβ, which suppress pro-inflammatory responses (25). Treg
cells induce the conversion of dendritic cells to a tolerogenic
state which hampers IL-2-dependent activation of CD8+ T cells
and natural killer cells (25).
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FIGURE 2 | Pattern shift visual evoked potentials showed a marked delay of the P100 component at 15′ (upper) and at 60′ (lower) in the left eye (P100 latency at 15′:
111ms in the left eye, 98ms in the right eye; P100 latency at 60′: 114ms in the left eye, 97ms in the right eye).
Furthermore, a reduction in IL10-producing B-regulatory
(Breg) cells compartment has been reported in CVID patients
in two studies (26, 27).Breg cells are responsible for negative
modulation of immune responses, and their dysregulation or
absence may trigger inflammatory or autoimmune diseases
(26, 28). The regulatory functions of these B cells are mainly
associated with their production of IL-10 and TGF-β, which
stimulate the expansion of Treg cells, restore TH1/TH2 balance,
and inhibit TH17 cells (26, 28). Moreover, there is evidence that
the number and abilities of Breg cells increase in response to
inflammation and autoimmunity, thus limiting the spread and
severity of these processes (28). Therefore, the reduction of Treg
cells and failure in Breg compartment expansion and activation
might account for the increased incidence of autoimmune
diseases in CVID patients. Other alterations that can be observed
include impaired somatic hypermutation in B cells, and defects
in dendritic cells functions (29).
Despite antibody production in response to antigens is
reduced or even lacking, the generation of autoantibodies
might, at the same time, be excessive (15). Thus, testing for
autoantibodies levels should be performed and may be a
useful tool for diagnosis, whenever there is clinical suspicion,
although a negative result does not exclude autoimmunity.
Conversely, detection of infectious agents in CVID patients
generally requires the use of molecular diagnostic techniques,
as antibody response to exogenous antigens is ineffective
and the use of immunoglobulin replacement therapy
may further challenge the validity of serological findings
(1).
Patients with CVID should be monitored periodically in
experienced centers. They should receive adequate replacement
therapy with immunoglobulins, physiotherapy, and prophylactic
antibiotic therapy if necessary, and they should be promptly
diagnosed and treated for any CVID complications which could
arise during follow up (2).
Optic neuritis (ON) is rarely infectious in nature (30–32).
Frequently, optic nerve involvement may occur in concomitance
with neuroretinis, characterized by optic disc edema andmacular
exudates (30). However, given their increased susceptibility to
infections, microbial agents must be thoroughly ruled out in
CVID patients. Among infectious causes of optic neuropathy, the
most commonly isolated agents are Bartonella henselae, Borrelia
burgdorferi, Treponema pallidum, Mycobacterium tuberculosis,
Herpesviruses, Arboviruses, Toxoplasma (14, 30–32). In our
patients, a wide range of possible infectious causes of ON have
been investigated and excluded.
Isolated ON may be the presenting symptom of MS (33).
Patients with no lesions on baseline MRI present a 25% risk of
developing clinically definite MS in the long term, comparing
to 75% risk of patients with abnormal scans (33). Among
patients with normal baseline MRI, further risk factors are
female sex, normal optic disc appearance, and typical clinical
features (33).
A less common cause of isolated ON is NMOSD. AQP4
antibodies can be detected in approximately 5.8% of patients
with acute ON (34). NMOSD is characterized by recurrent
attacks of unilateral or bilateral optic neuritis, transverse myelitis,
and acute brainstem or area postrema syndromes (12). Overall,
AQP4 antibodies are detectable in∼88% of patients with clinical
features of NMOSD (35). Detectable serumMOG autoantibodies
can be found in a minority of patients with clinical characteristics
of NMOSD, and their presence is associated with younger age
at onset, male sex and a reduced risk of recurrence comparing
to patients with AQP4 seropositivity (36, 37). In our patient,
serological analysis for AQP4 and MOG autoantibodies turned
out negative.
In addition to that, ON can occur in a variety of systemic
inflammatory conditions, such as Systemic Lupus Eritematosus,
Sjogren’s syndrome, and granulomatosis with polyangiitis (30).
In these cases, additional clinical findings and associated
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autoantibodies may aid in the diagnosis. Furthermore, a great
mimicker such as sarcoidosis may present with a typical ON
(30). These diseases seemed unlikely in our patient in view of the
negative serologic studies and normal PET/CT scans.
Although rare, optic neuropathies may arise in the setting
of primary CNS Non-Hodgkin lymphomas (NHL) and
paraneoplastic syndromes (38–43). As in CVID there is an
increased risk of developing NHL (4, 44, 45), total body PET/CT
and CSF analysis were performed, yielding negative results.
Polyclonal lymphocytic infiltration (i.e., granulomas,
unexplained hepatomegaly, persistent lymphadenopathy,
splenomegaly, lymphocytic enteropathy, lymphoid interstitial
pneumonitis) is a potential CVID-related complication
(2, 45, 46). Nevertheless, lymphocytic infiltration of the CNS
is extremely rare. In a case series, possible radiologic findings
were mass lesions, leptomeningeal enhancement, non-specific
white matter lesions, and neurohypophysis abnormalities, and
most common clinical presentations were seizures, headache,
vision loss, cognitive impairment, and focal deficits (46). Most
pathologic lesions consisted of granulomatous formations.
CSF findings include increased total proteins with or without
lymphocytic pleocytosis. Treatment of CNS granulomatous
disease is empirical and based on scant case reports or case
series (2, 46). Steroids, intravenous immunoglobulins and
other immunosuppressive agents have been tried, alone and in
combination, mostly leading to recovery in the short term. Our
patient displayed a clinical phenotype of systemic polyclonal
lymphocytic infiltration, therefore CNS involvement should
be held into account, although isolated optic nerve infiltration
has never been described and increased uptake in PET scans is
expected in case of lymphomatous granulomatosis.
Having ruled out other possible causes of ON, the occurrence
of a clinically isolated syndrome (CIS) appears as the most
likely diagnosis. As mentioned, the risk of developing MS in
the long term is around 25% in patient with CIS and a normal
baseline MRI scan (33). The diagnosis of MS requires clinical
or radiological evidence of dissemination in time and space, or
the presence of oligoclonal bands in the CSF (47), therefore
clinical and instrumental follow-up is needed in these cases.
Early intravenous methylprednisolone at high doses (1 g/die)
was shown to accelerate visual recovery and reduce the risk of
conversion to MS in the first 2 years after ON, but no differences
in comparison with controls were seen in the long run (48–50).
Patients with typical, isolated ONwithout furtherMRI lesions are
usually monitored, andMRI performed at regular intervals might
enable and earlier diagnosis of MS (11). If the disease converts to
MS, relapsing in the subsequent 2 years, then disease-modifying
drugs can be prescribed (11).
MS is a complex and heterogeneous disease whose
pathogenesis has not been completely clarified yet (51). It
was originally considered a T cell-mediated disease, but
evidence regarding the involvement of additional cell types,
including B cells, has been accumulating over the years (52).
The pathogenic process appears to begin with the activation
of peripheral autoreactive T cells by mimicry or bystander
activation, followed by their infiltration into the CNS, where
they lead to the activation of additional cells, such as B cells,
monocytes, astrocytes, andmicroglia (52). Several studies suggest
that Breg cells might be involved in MS pathogenesis. Indeed,
B cells from MS patients were shown to have a significantly
diminished capacity to secrete IL-10 in response to stimuli
(53–55). However, other studies did not confirm these results
(56, 57). These contrasting findings might be due to the use of
different stimulation protocols, different definitions of Bregs,
and variations in patients cohorts and MS subsets (52). Several
studies have revealed that declines in the number and functions
of Treg cells contribute to the development of autoimmune
diseases (22, 24, 25). A recent work showed that both naïve
and memory Treg cells are reduced in in MS patients and that
Treg cells mainly express the FoxP3 isoform lacking exon 2
(58). Additionally, they observed increased membrane levels
of PD-1, the inhibitory receptor of Treg subsets (58). Taken
altogether, these findings seem to suggest a potential role of
B and T regulatory cells in the pathogenesis of autoimmune
demyelinating CNS disorders, which were previously shown to
be involved in the pathogenesis of autoimmune complications
of CVID. Whether these cells play a role in prevention of
development of autoimmune diseases or only in containing and
cessating altered immune responses is not clear. However, they
might represent a potential pathogenic link between these two
distinct conditions.
CONCLUDING REMARKS
To date, there is only one report of ON in a patient with
CVID, presenting as bilateral clinically isolated demyelinating
syndrome (10). Our case further strengthens this association,
thus encouraging clinicians to consider the possibility
of acute demyelination in CVID patients with unilateral
ophthalmological symptoms. Establishing a connection between
these diseases may have a significant impact on clinical practice
and patients’ well-being, as early steroidal therapy in ON
results in accelerated clinical improvement and reduced risk
of developing MS in the subsequent 2 years (48–50). However,
as CVID patients are prone to infections and hematologic
malignancies as well, these conditions need to be carefully
excluded on the basis of clinical, laboratory, and instrumental
findings.
In conclusion, neurological manifestations in CVID are
challenging for both their atypical presentation and for the
nature of the disease itself, which can provoke or mimic several
diseases (2, 9). Autoimmune diseases, especially cytopenias,
occur in 25% of CVID patients, and splenomegaly is also a
common finding in such patients. Dysregulation in suppressive
function of regulatory T and B cell subsets has been described
in association with these clinical findings. Quantitative and
qualitative alterations in these cellular populations might
represent the link between CNS demyelination and CVID.
However, further studies are needed in order to better elucidate
these connection. CVID remains a largely obscure pathologic
entity, and a better comprehension of its pathogenic mechanisms
and clinical manifestations is essential to better understand and
treat this severe condition.
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